Kezar Life Sciences to Present Complete Results from the Phase 2 MISSION Trial of Zetomipzomib in Patients with Lupus Nephritis at the American Society of Nephrology’s Kidney Week 2022 Annual Meeting
October 14 2022 - 7:00AM
Business Wire
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage
biotechnology company discovering and developing breakthrough
treatments for immune-mediated and oncologic disorders, today
announced that four posters will be presented at the upcoming
American Society of Nephrology’s (ASN) Kidney Week 2022 Annual
Meeting, which will take place November 3 – 6, 2022 in Orlando, FL.
Of note, the Phase 2 MISSION poster will include the full data set
from the concluded study, with all 17 evaluable patients completing
the 37-week trial. There will be additional MISSION data included
in the poster presentation that are not available in the
abstract.
Poster Presentation Details:
Abstract Title: Zetomipzomib (KZR-616), A First-in-Class
Selective Immunoproteasome Inhibitor for the Treatment of Lupus
Nephritis: Preliminary Results from the Phase 2 MISSION Study
Session: Glomerular Diseases: Clinical, Outcomes, Trials - I
[PO1303-1] Date/Time: November 3, 2022 from 10:00 AM - 12:00
PM ET Presenter: Dr. Samir V. Parikh, MD, Associate
Professor of Medicine, Division of Nephrology, The Ohio State
University Wexner Medical Center
Abstract Title: Comorbidities and Poor Long-Term Outcomes
of Lupus Nephritis in Adult Patients in the United States
Session: Glomerular Diseases: Lupus and Vasculitis
[PO1302-2] Date/Time: November 4, 2022 from 10:00 AM - 12:00
PM ET Presenter: Dr. Isabelle Ayoub, MD, Associate Professor
of Clinical Medicine, Division of Nephrology, The Ohio State
University Wexner Medical Center
Abstract Title: Poor Health-Related Quality of Life in
Adult Patients with Lupus Nephritis Poster Session:
Glomerular Diseases: Lupus and Vasculitis [PO1302-2]
Date/Time: November 4, 2022 from 10:00 AM - 12:00 PM ET
Presenter: Dr. Y. K. O. Teng, MD, PhD, Department of
Nephrology, Leiden University Medical Center
Abstract Title: Substantial Economic Burden Associated
with the Management of Lupus Nephritis in Adult Patients in the
United States Session: Glomerular Diseases: Lupus and
Vasculitis [PO1302-2] Date/Time: November 4, 2022 from 10:00
AM - 12:00 PM ET Presenter: Dr. Brad Rovin, MD, FASN, FACP,
Professor of Medicine and Pathology, The Lee A. Hebert Professor of
Nephrology, Director, Division of Nephrology, The Ohio State
University Wexner Medical Center
The accepted ASN abstracts will be made available today on the
congress platform here. Following the conference, the presentation
materials will be available in the “Scientific Publications”
section of Kezar Life Science’s website at
www.kezarlifesciences.com.
About Zetomipzomib (KZR-616)
Zetomipzomib (KZR-616) is a novel, first-in-class, selective
immunoproteasome inhibitor with broad therapeutic potential across
multiple autoimmune diseases. Preclinical research demonstrates
that selective immunoproteasome inhibition results in a broad
anti-inflammatory response in animal models of several autoimmune
diseases, while avoiding immunosuppression. Data generated from
Phase 1 clinical trials provide evidence that zetomipzomib exhibits
a favorable safety and tolerability profile for development in
severe, chronic autoimmune diseases.
About Kezar Life Sciences
Kezar Life Sciences is a clinical-stage biopharmaceutical
company discovering and developing breakthrough treatments for
immune-mediated and oncologic disorders. The company is pioneering
first-in-class, small-molecule therapies that harness master
regulators of cellular function to inhibit multiple drivers of
disease via single, powerful targets. Zetomipzomib, its lead
development asset, is a selective immunoproteasome inhibitor being
evaluated in a Phase 2 clinical trial in lupus nephritis. This
product candidate also has the potential to address multiple
chronic immune-mediated diseases. KZR-261 is the first anti-cancer
clinical candidate from the company’s platform targeting the Sec61
translocon and the protein secretion pathway. An open-label
dose-escalation Phase 1 clinical trial of KZR-261 to assess safety,
tolerability and preliminary tumor activity in solid tumors is
underway. For more information, visit
www.kezarlifesciences.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221014005025/en/
Investor Contact: Gitanjali Jain Vice President, Investor
Relations and External Affairs gjain@kezarbio.com Media
Contact: Julia Deutsch Solebury Strategic Communications
jdeutsch@soleburystrat.com
Kezar Life Sciences (NASDAQ:KZR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Kezar Life Sciences (NASDAQ:KZR)
Historical Stock Chart
From Sep 2023 to Sep 2024